Tonix (TNXP) COO awarded two stock option grants under 2020 plan

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. reported that Chief Operating Officer Jessica Edgar Morris received two grants of stock options. One grant covers 39,012 stock options and the other covers 39,011 stock options, both awarded at an exercise price of $0.00 per share.

According to the vesting terms, one-third of each option grant vests on the first anniversary of issuance, with the remaining portion vesting in equal monthly installments over the following 36 months. The options were granted under the company’s Amended and Restated 2020 Stock Incentive Plan.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider MORRIS JESSICA EDGAR

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	39,012	$0.00	--
Grant/Award	Stock Option	39,011	$0.00	--

Holdings After Transaction: Stock Option — 39,012 shares (Direct)

Footnotes (1)

1. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MORRIS JESSICA EDGAR

(Last) (First) (Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP

200 CONNEL DRIVE, SUITE 3100

(Street)

BERKLEY HEIGHTS NY 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$14.29	02/24/2026		A		39,012		02/24/2027(1)	02/24/2036	Common Stock	39,012	$0.00(2)	39,012	D
Stock Option	$17.8625	02/24/2026		A		39,011		02/24/2027(1)	02/24/2036	Common Stock	39,011	$0.00(2)	39,011	D

Explanation of Responses:

1. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months.

2. The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.

	/s/ Jessica Morris	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TNXP report for Jessica Edgar Morris?

Tonix Pharmaceuticals reported that Chief Operating Officer Jessica Edgar Morris received two stock option grants. One grant covers 39,012 options and the other 39,011 options, both at an exercise price of $0.00 per share as part of her equity compensation.

Are the TNXP stock options granted to Jessica Edgar Morris immediately vested?

The stock options are not immediately vested. One-third of each grant vests on the first anniversary of issuance, while the remaining two-thirds vest in equal monthly installments over the following 36 months, creating a multi-year retention and incentive structure.

Under which plan were Jessica Edgar Morris’s TNXP stock options granted?

The option grants were made under Tonix Pharmaceuticals’ Amended and Restated 2020 Stock Incentive Plan, as amended. This plan governs the terms of equity-based awards, aligning executive compensation with the company’s long-term performance and shareholder interests through structured vesting.

What is the exercise price of the TNXP stock options granted to the COO?

Both stock option grants to the Chief Operating Officer have an exercise price of $0.00 per share. This indicates they are compensatory awards rather than open-market purchases, designed to provide potential upside if the company’s share value increases over time.

How many TNXP stock option grants did the COO receive in this filing?

The filing shows two separate stock option grants to the Chief Operating Officer. One grant is for 39,012 options and the other for 39,011 options, each subject to identical time-based vesting conditions spanning up to four years from issuance.